Paul Lizzul, M.D., Ph.D., is the Chief Medical Officer at ANAPTYSBIO INC, a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics. Dr. Lizzul brings a wealth of experience in clinical development, having worked in the biopharmaceutical industry for over two decades. He holds both a medical degree and a doctoral degree, which uniquely positions him to lead the clinical strategy and development of ANAPTYSBIO's innovative pipeline. Before joining ANAPTYSBIO, Dr. Lizzul held significant roles at several prominent biotechnology companies. He served as the Chief Medical Officer at Arena Pharmaceuticals, where he was instrumental in advancing the company's pipeline of drugs through various stages of clinical trials. Prior to Arena, he worked at Amgen, where he contributed to the development of several successful therapeutics. His extensive experience in leading clinical development programs has been crucial in driving ANAPTYSBIO's mission to bring transformative treatments to patients with serious diseases. As Chief Medical Officer at ANAPTYSBIO, Dr. Lizzul is responsible for overseeing the clinical development of the company's lead programs, including its immunology and oncology assets. His strategic vision and leadership have been pivotal in guiding the company through the complexities of clinical trials and regulatory processes. Under his guidance, ANAPTYSBIO continues to make significant strides in advancing its novel therapies towards commercialization, with the ultimate goal of improving patient outcomes and addressing unmet medical needs.